Filtered By:
Management: Food and Drug Administration (FDA)

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 199 results found since Jan 2013.

Podcast: A quick chat with Farzad Mostashari
Friday is the last day on the job for departing national health IT coordinator Dr. Farzad Mostashari, who is stepping down after four years with the Office of the National Coordinator for Health Information Technology, including the last two years as head of ONC. I was in Washington two weeks ago and stopped by the HHS headquarters for ONC’s Consumer Health IT Summit, the opening event of National Health IT Week, and got a few minutes with Mostashari. (I suppose that was good timing, because I imagine the government shutdown that took effect this week would have canceled the summit and even prevented me from entering...
Source: Neil Versel's Healthcare IT Blog - October 3, 2013 Category: Technology Consultants Authors: Neil VerselNeil Versel Tags: ARRA consumerism EMR/EHR health IT health reform Healthcare IT HHS HIPAA meaningful use ONC podcast CHIME Farzad Mostashari patient engagement Source Type: blogs

What’s the best skin lightening ingredient? The Beauty Brains Show episode 35
Do skin bleaching products really work? Are the ingredients safe? This week Randy and I explain everything you need to know about skin lightening.     Click below to play Episode 35 or click “download” to save the MP3 file to your computer. Show notes Beauty Science News: 7 ways to spot a real expert As you know we like to promote skeptical thinking, especially when it comes to beauty products. I found an interesting article from Forbes that gives 7 ways to tell you’re dealing with a real expert and not someone who’s just faking it. Real experts focus on their field, not themselves. Real experts hav...
Source: thebeautybrains.com - June 17, 2014 Category: Consumer Health News Authors: Perry RomanowskiThe Beauty Brains Tags: Best Podcast Problems Safety Source Type: blogs

October 6 2015 Issue
1) Evaluation of outcome measures for neurogenic claudication and 2) Topic of the month: Neurology Today: Recent Publications. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. John Markman about his paper on a patient-centered approach for evaluation of outcome measures for neurogenic claudication. Dr. Ted Burns is interviewing Dr. Robert Gross for our “What's Trending” feature of the week about Neurology's spoke journals. In the next part of the p...
Source: Neurology Podcast - October 5, 2015 Category: Neurology Authors: American Academy of Neurology Source Type: podcasts

#MayoClinicRadio podcast: 4/6/19
Listen: Mayo Clinic Radio 4/6/19 On the Mayo Clinic Radio podcast, Dr. Robert Kraichely, a Mayo Clinic gastroenterologist, discusses?treatment for irritable bowel syndrome.?Also on the podcast, Dr. Jennifer Vande Voort, a Mayo Clinic psychiatrist, discusses esketamine nasal spray -- a fast-acting treatment for?depression?that?recently was approved by the Food and Drug Administration. And Dr. Nipunie Rajapakse, [...]
Source: News from Mayo Clinic - April 7, 2019 Category: Databases & Libraries Source Type: news

BMJ podcast - high risk devices for rare conditions
Two articles on bmj.com look at high risk devices for rare conditions, and how the US Food and Drug Administration regulates them. Joining us to discuss the problems are Rita Redberg, professor of medicine at the University of California San Francisco, and Aaron Kesselheim, assistant professor of medicine at the Harvard School of Public...
Source: The BMJ Podcast - January 24, 2014 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts

Podcast: Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events
Most Cochrane Reviews seek to cover both the benefits and harms of interventions, but the complexity of the research on the adverse effects of some treatments means that a few reviews are dedicated to just the potential harms. One of these, on one of the drugs used for treating asthma was updated in September 2019, and lead author, Sadia Janjua from the Population Health Research Institute at the University of London in the UK, tells us about the latest findings in this podcast.The standard treatment for people with asthma is a low-dose inhaled corticosteroid. But if this does not control their asthma on its own, many guid...
Source: Cochrane News and Events - February 14, 2020 Category: Information Technology Authors: Lydia Parsonson Source Type: news

FDA Drug Safety Podcast: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C
Source: FDA Drug Safety Podcasts - January 27, 2021 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts

FDA Drug Safety Podcast: FDA revises description of mental health side effects of stop-smoking medicines Chantix and Zyban to reflect clinical trial findings
Source: FDA Drug Safety Podcasts - January 27, 2021 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts

FDA Drug Safety Podcast: FDA warns about serious liver injury with Ocaliva (obeticholic acid) for rare chronic liver disease
Listen to an audio podcast of the September 21, 2017 FDA Drug Safety Communication: FDA warns about serious liver injury with Ocaliva (obeticholic acid) for rare chronic liver disease. Ocaliva is being incorrectly dosed in some patients with moderate to severe decreases in liver function, resulting in an increased risk of serious liver injury and death. The recommended dosing and monitoring for patients on Ocaliva are described in the current drug label. We are working with the drug manufacturer, Intercept Pharmaceuticals, to address these safety concerns.
Source: FDA Drug Safety Podcasts - February 9, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts

FDA Drug Safety Podcast: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks
Listen to an audio podcast of the September 20, 2017 FDA Drug Safety Communication in which FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants. The combined use of these drugs increases the risk of serious side effects; however, the harm caused by untreated opioid addiction can outweigh these risks.
Source: FDA Drug Safety Podcasts - February 9, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts

FDA Drug Safety Podcast: FDA recommends separating dosing of potassium-lowering drug sodium polystyrene sulfonate (Kayexalate) from all other oral drugs
Listen to an audio podcast of the September 6, 2017 FDA Drug Safety Communication titled "FDA recommends separating dosing of potassium-lowering drug sodium polystyrene sulfonate (Kayexalate) from all other oral drugs". A study found that sodium polystyrene sulfonate binds to many commonly prescribed oral medicines, decreasing the absorption and therefore effectiveness of those oral medicines.
Source: FDA Drug Safety Podcasts - February 9, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts

FDA Drug Safety Podcast: FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs; review to continue
Listen to an audio podcast of the May 22, 2017 FDA Drug Safety Communication. FDA announced that to date a review has not identified adverse health effects from gadolinium retained in the brain after the use of gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI); review to continue.
Source: FDA Drug Safety Podcasts - February 9, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts

FDA Drug Safety Podcast: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR)
Listen to an audio podcast of the May 16, 2017, FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR).
Source: FDA Drug Safety Podcasts - February 9, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts